Personal information

No personal information available

Activities

Collapse all

Works (37)

Targeted drug conjugates in cancer therapy: Challenges and opportunities

Pharmaceutical Science Advances
2024-12 | Journal article
DOI: 10.1016/j.pscia.2024.100048
Contributors: Geng Jia; Yuqi Jiang; Xiaoyang Li
Source: check_circle
Crossref

Biological function and small molecule inhibitors of histone deacetylase 11

European Journal of Medicinal Chemistry
2024-10 | Journal article
DOI: 10.1016/j.ejmech.2024.116634
Contributors: Geng Jia; Jinyu Liu; Xinlu Hou; Yuqi Jiang; Xiaoyang Li
Source: check_circle
Crossref

Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia

European Journal of Medicinal Chemistry
2024-10 | Journal article
DOI: 10.1016/j.ejmech.2024.116663
Contributors: Enqiang Liu; Yuxin Chen; Mengting Qin; Kairui Yue; Simin Sun; Yuqi Jiang; Xiaoyang Li
Source: check_circle
Crossref

An overview of sphingosine‐1‐phosphate receptor 2: Structure, biological function, and small‐molecule modulators

Medicinal Research Reviews
2024-09 | Journal article
DOI: 10.1002/med.22044
Contributors: Wanting Hao; Dongdong Luo; Yuqi Jiang; Shengbiao Wan; Xiaoyang Li
Source: check_circle
Crossref

Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax

Marine Drugs
2024-05-28 | Journal article
DOI: 10.3390/md22060250
Contributors: Wanting Hao; Leyan Wang; Tongqiang Xu; Geng Jia; Yuqi Jiang; Chong Qin; Xiaoyang Li
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells

European Journal of Medicinal Chemistry
2024-02 | Journal article
DOI: 10.1016/j.ejmech.2024.116127
Contributors: Kairui Yue; Simin Sun; Enqiang Liu; Jinyu Liu; Baogeng Hou; Kangjing Qi; C. James Chou; Yuqi Jiang; Xiaoyang Li
Source: check_circle
Crossref

Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells

European Journal of Medicinal Chemistry
2023-12 | Journal article
DOI: 10.1016/j.ejmech.2023.115915
Contributors: Jingjing Deng; Baogeng Hou; Xiaohan Hou; Yuxin Chen; Tao Zhang; Hua Chen; Yuanze Wang; Xiaoyang Li
Source: check_circle
Crossref

Discovery of Novel 2,3-Dihydro-1<i>H</i>-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis

Journal of Medicinal Chemistry
2023-12-14 | Journal article | Conceptualization, Funding acquisition, Investigation, Writing - review & editing, Supervision
DOI: 10.1021/acs.jmedchem.3c01511
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Contributors: Simin Sun; Zhuoyue Li; Chao Huang; Jinyu Liu; Qixin Yu; Xiaolin Jiang; Kairui Yue; Jianchun Zhao; Tongqiang Xu; Yan-Kai Liu et al.
Source: Self-asserted source
Xiaoyang Li

Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer

European Journal of Medicinal Chemistry
2023-11 | Journal article
DOI: 10.1016/j.ejmech.2023.115752
Contributors: Geng Jia; Kangjing Qi; Baogeng Hou; Kairui Yue; Tongqiang Xu; Yuqi Jiang; Xiaoyang Li
Source: check_circle
Crossref

Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer

Molecules
2023-08 | Journal article | Author
DOI: 10.3390/molecules28176343
Contributors: Jian Zhang; Simin Sun; Jinyu Liu; Liang Zhang; Di Guo; Naixin Zhang; Jun Zhao; Dexin Kong; Tongqiang Xu; Xuejian Wang et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine

Journal of Medicinal Chemistry
2023-03-23 | Journal article
DOI: 10.1021/acs.jmedchem.3c00006
Contributors: Liang Zhang; Kangjing Qi; Jie Xu; Yan Xing; Xuejian Wang; Ling Tong; Zengguo He; Wenfang Xu; Xiaoyang Li; Yuqi Jiang
Source: check_circle
Crossref

1,2-Isoselenazol-3(2H)-one derivatives as NDM-1 inhibitors displaying synergistic antimicrobial effects with meropenem on NDM-1 producing clinical isolates

Bioorganic Chemistry
2022-12 | Journal article
DOI: 10.1016/j.bioorg.2022.106153
Contributors: Kairui Yue; Chen Xu; Zhihao Wang; Wandong Liu; Chenyu Liu; Ximing Xu; Yan Xing; Sheng Chen; Xiaoyang Li; Shengbiao Wan
Source: check_circle
Crossref

Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer

Journal of Medicinal Chemistry
2022-11-10 | Journal article | Author
DOI: 10.1021/acs.jmedchem.2c00958
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Contributors: Dongdong Luo; Xiaochun Liu; Leilei Jiang; Zhikun Guo; Yan Lv; Xiaochen Tian; Xiaoyan Wang; Shuxiang Cui; shengbiao wan; Xianjun Qu et al.
Source: Self-asserted source
Xiaoyang Li

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation

Journal of Medicinal Chemistry
2022-09-22 | Journal article
DOI: 10.1021/acs.jmedchem.2c00853
Contributors: Kairui Yue; Simin Sun; Geng Jia; Mengting Qin; Xiaohan Hou; C. James Chou; Chao Huang; Xiaoyang Li
Source: check_circle
Crossref

Discovery of the First Vitamin K Analogue as a Potential Treatment of Pharmacoresistant Seizures

Journal of Medicinal Chemistry
2020-06-11 | Journal article
DOI: 10.1021/acs.jmedchem.0c00168
Contributors: Xiaoyang Li; Richard A. Himes; Lyndsey C. Prosser; Charleston F. Christie; Emma Watt; Sharon F. Edwards; Cameron S. Metcalf; Peter J. West; Karen S. Wilcox; Sherine S. L. Chan et al.
Source: check_circle
Crossref

Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity

Journal of Medicinal Chemistry
2020-05-28 | Journal article
DOI: 10.1021/acs.jmedchem.0c00442
Contributors: Xiaoyang Li; Yuqi Jiang; Yuri K. Peterson; Tongqiang Xu; Richard A. Himes; Xin Luo; Guilin Yin; Elizabeth S. Inks; Nathan Dolloff; Stephanie Halene et al.
Source: check_circle
Crossref

Discovery of N-(2-Aminophenyl)-4-(bis(2-chloroethyl)amino)Benzamide as a Potent Histone Deacetylase Inhibitor

Frontiers in Pharmacology
2019-08-30 | Journal article
DOI: 10.3389/fphar.2019.00957
Part of ISSN: 1663-9812
Source: Self-asserted source
Xiaoyang Li

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

Journal of Medicinal Chemistry
2019-04-25 | Journal article
DOI: 10.1021/acs.jmedchem.8b01597
Contributors: Xuewu Liang; Jie Zang; Xiaoyang Li; Shuai Tang; Min Huang; Meiyu Geng; C. James Chou; Chunpu Li; Yichun Cao; Wenfang Xu et al.
Source: check_circle
Crossref

Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics

Advances in Cancer Research
2018 | Book chapter
DOI: 10.1016/bs.acr.2018.02.006
Part of ISBN: 9780128151273
Part of ISSN: 0065-230X
Source: Self-asserted source
Xiaoyang Li

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously

Journal of Medicinal Chemistry
2018-06-28 | Journal article
DOI: 10.1021/acs.jmedchem.8b00384
Contributors: Jie Zang; Xuewu Liang; Yongxue Huang; Yuping Jia; Xiaoyang Li; Wenfang Xu; C. James Chou; Yingjie Zhang
Source: check_circle
Crossref

Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status

Journal of Medicinal Chemistry
2018-03-22 | Journal article
DOI: 10.1021/acs.jmedchem.8b00136
Contributors: Xiaoyang Li; Yuri K. Peterson; Elizabeth S. Inks; Richard A. Himes; Jiaying Li; Yingjie Zhang; Xiujie Kong; C. James Chou
Source: check_circle
Crossref

HDAC1 localizes to the mitochondria of cardiac myocytes and contributes to early cardiac reperfusion injury

Journal of Molecular and Cellular Cardiology
2018-01 | Journal article
DOI: 10.1016/j.yjmcc.2017.12.004
Part of ISSN: 0022-2828
Source: Self-asserted source
Xiaoyang Li

Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy

European Journal of Medicinal Chemistry
2018-01 | Journal article
DOI: 10.1016/j.ejmech.2017.11.074
Part of ISSN: 0223-5234
Source: Self-asserted source
Xiaoyang Li

Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study

European Journal of Medicinal Chemistry
2017-07 | Journal article
DOI: 10.1016/j.ejmech.2017.03.069
Part of ISSN: 0223-5234
Source: Self-asserted source
Xiaoyang Li

Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy

Anti-Cancer Agents in Medicinal Chemistry
2017-06-05 | Journal article
DOI: 10.2174/1871520616666160901150427
Part of ISSN: 1871-5206
Source: Self-asserted source
Xiaoyang Li

Design, synthesis, and preliminary bioactivity evaluation of N 1 -hydroxyterephthalamide derivatives with indole cap as novel histone deacetylase inhibitors

Chemical Biology & Drug Design
2017-01 | Journal article
DOI: 10.1111/cbdd.12819
Part of ISSN: 1747-0277
Source: Self-asserted source
Xiaoyang Li

Discovery of a novel chimeric ubenimex–gemcitabine with potent oral antitumor activity

Bioorganic & Medicinal Chemistry
2016-11 | Journal article
DOI: 10.1016/j.bmc.2016.09.033
Part of ISSN: 0968-0896
Source: Self-asserted source
Xiaoyang Li

Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents

Chemical Biology & Drug Design
2016-10 | Journal article
DOI: 10.1111/cbdd.12778
Part of ISSN: 1747-0277
Source: Self-asserted source
Xiaoyang Li

Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent

European Journal of Medicinal Chemistry
2016-10 | Journal article
DOI: 10.1016/j.ejmech.2016.05.068
Part of ISSN: 0223-5234
Source: Self-asserted source
Xiaoyang Li

PXD101 analogs withL-phenylglycine-containing branched cap as histone deacetylase inhibitors

Chemical Biology & Drug Design
2016-10 | Journal article
DOI: 10.1111/cbdd.12787
Part of ISSN: 1747-0277
Source: Self-asserted source
Xiaoyang Li

Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU

Medicinal Chemistry
2016-01-05 | Journal article
DOI: 10.2174/1573406411666150714111045
Part of ISSN: 1573-4064
Source: Self-asserted source
Xiaoyang Li

Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors

Bioorganic & Medicinal Chemistry
2015-10 | Journal article
DOI: 10.1016/j.bmc.2015.08.040
Part of ISSN: 0968-0896
Source: Self-asserted source
Xiaoyang Li

Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor

Journal of Medicinal Chemistry
2015-05-28 | Journal article
DOI: 10.1021/acs.jmedchem.5b00317
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Source: Self-asserted source
Xiaoyang Li

Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity

European Journal of Medicinal Chemistry
2015-01 | Journal article
DOI: 10.1016/j.ejmech.2014.10.077
Part of ISSN: 0223-5234
Source: Self-asserted source
Xiaoyang Li

Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors

Bioorganic & Medicinal Chemistry
2014-06 | Journal article
DOI: 10.1016/j.bmc.2013.12.025
Part of ISSN: 0968-0896
Source: Self-asserted source
Xiaoyang Li

Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer

Current Drug Targets
2014-04 | Journal article
DOI: 10.2174/1389450115666140306152642
Part of ISSN: 1389-4501
Source: Self-asserted source
Xiaoyang Li

Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity

Journal of Medicinal Chemistry
2014-04-24 | Journal article
DOI: 10.1021/jm401877m
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Source: Self-asserted source
Xiaoyang Li

Peer review (27 reviews for 5 publications/grants)

Review activity for ACS omega. (1)
Review activity for Bioorganic chemistry. (7)
Review activity for European journal of medicinal chemistry. (5)
Review activity for Journal of medicinal chemistry. (11)
Review activity for Pharmaceutical science advances. (3)
How many people are using ORCID?